Nicox

News

Nicox plans filings for glaucoma after phase 3 win

Nicox is on track to file for approval of its therapy for eyesight-robbing disease glaucoma in the US and China after a second positive phase 3 trial.

News

Nicox glaucoma drug works, but not as well as hoped

Nicox has had both good and bad news from a much-anticipated phase 3 trial of its glaucoma therapy candidate NCX 470.

News

CEPI steps in to fund Moderna's pandemic flu jab

Thanks to CEPI, Moderna's H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by HHS Sec Kennedy.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks